The United Kingdom’s National Health Service on Tuesday introduced what it described as a “life changing treatment” for sickle cell illness (SCD).
“Known as Crizanlizumab, the new drug will be delivered by a transfusion drip and works by binding to a protein in the blood cells to prevent the restriction of blood and oxygen supply that lead to a sickle cell crisis,” a press release from the NHS mentioned.
The drug is anticipated to assist individuals residing with SCD have “a much better quality of life.”
READ ALSO: Nigeria Missing From UK’s Valid COVID-19 Vaccine Certificate List
SCD, in accordance with the World Health Organisation (WHO), is a significant genetic illness the place the conventional spherical form of pink blood cells change into like crescent moons, resulting in blood clots which might trigger excessive ache within the again, chest, palms and toes.
There isn’t any identified remedy but, besides stem cell transplants, a process which requires a donor, is pricey, emotionally exhausting and carries deadly dangers.
The illness is prevalent in Nigeria, maybe greater than wherever on this planet.
About 30 p.c of the inhabitants are carriers of the sickle cell trait. And virtually three p.c of Nigerians live with SCD.
It is taken into account to be the most typical genetic dysfunction in Nigeria, however testing isn’t obtainable to the overwhelming majority of infants, resulting in 1000’s of deaths yearly.